Nidan, we can't underestimate the role of large institutional investors putting their thumbs on the scales of pharma competition. I'm concerned about Blackrock(Larry Fink) who along with Vanguard is at the top of institutional investors. Blackrock is the 2nd largest holder of Biogen ( 14.3 mil shares, $3.6B and 9.9% of shares). It is also in the top 3 of holders of Lilly, Pfizer and Merck as well as other large Pharmas. Blackrock has a lot more invested in our competitors than in Anavex and I wouldn't put it past Fink to tip the scales. Here is a 2021 article on the subject of large institutional investors efforts in controlling the market.
News 
Market Data 
Discover 
